^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BGB-21447
i
Other names: BGB-21447, BGB21447, BGB 21447
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BeiGene
Drug class:
Bcl2 inhibitor
Related drugs:
8ms
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
P1, N=85, Recruiting, BeiGene
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
MYC translocation
|
BGB-21447
over1year
Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
P1, N=66, Recruiting, BeiGene | Not yet recruiting --> Recruiting
Enrollment open
|
BCL2 (B-cell CLL/lymphoma 2)
|
MYC translocation
|
BGB-21447
over1year
Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
P1, N=66, Not yet recruiting, BeiGene
New P1 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
MYC translocation
|
BGB-21447
Share via
